Core Viewpoint - STAAR Surgical Company strongly disagrees with the recommendation issued by Glass, Lewis & Co. regarding its pending merger with Alcon [1] Company Summary - STAAR Surgical is a global leader in phakic IOLs, specifically with its EVO family of Implantable Collamer® Lenses for vision correction [1] - The company is currently involved in a merger process with Alcon, a significant player in the eye care industry [1]

Core Points - Broadwood Partners and its affiliates announced that Glass Lewis, a prominent proxy advisory firm, recommended STAAR Surgical Company shareholders vote "AGAINST" the proposed acquisition by Alcon Inc. [1] Group 1 - Glass Lewis's recommendation highlights concerns regarding the acquisition terms announced on August 5, 2025 [1]

Core Viewpoint - Defender Capital opposes the proposed acquisition of STAAR Surgical Company by Alcon Inc., arguing that the offer of $28 per share significantly undervalues STAAR, especially in light of a previous offer of $58 per share that was rejected by the STAAR Board of Directors just sixteen months ago [1]. Group 1 - Defender Capital has been a significant shareholder of STAAR for over ten years and believes in the substantial value of the company [1]. - The recent positive projections and outlook from STAAR's management provide no compelling reason to sell the company at the proposed valuation [2]. - Defender Capital expresses disappointment that the STAAR Board is pursuing a transaction that does not reflect the standalone business prospects of STAAR [2].

Core Viewpoint - STAAR Surgical Company is recognized by independent industry analysts as having a favorable merger with Alcon, which offers compelling cash value for STAAR stockholders [1] Company Summary - STAAR Surgical Company is a global leader in phakic IOLs, specifically with its EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction [1] - The merger with Alcon is viewed as the best path forward for STAAR stockholders, providing a certain and premium cash value [1] Industry Summary - The commentary from independent analysts highlights the positive outlook for STAAR's stockholders following the merger with Alcon [1]

Core Viewpoint - Broadwood Partners, L.P. and its affiliates, holding approximately 27.5% of STAAR Surgical Company's outstanding common stock, are urging stockholders to vote against the proposed acquisition by Alcon Inc. on the terms announced on August 5, 2025 [1]. Group 1 - Broadwood has published a presentation to support its position against the acquisition [1]. - The acquisition is being contested on the basis of the terms outlined in the announcement made on August 5, 2025 [1].

Core Viewpoint - Kaskela Law LLC is investigating the fairness of the shareholder buyout offer made to STAAR Surgical Company, particularly focusing on whether the proposed price of $28.00 per share is adequate compared to the company's 52-week high of $38.60 per share, and concerns regarding conflicts of interest in the sales process [1]. Summary by Relevant Sections Shareholder Buyout Offer - STAAR Surgical Company has agreed to be acquired by Alcon at a price of $28.00 per share, which is significantly lower than its 52-week high of $38.60 per share [1]. - The investigation by Kaskela Law LLC aims to determine if the buyout proposal is fair and provides sufficient monetary consideration for STAAR's investors [1]. Conflicts of Interest - Initial findings from the investigation suggest that there are significant conflicts of interest associated with the transaction, raising concerns about the fairness of the sales process and the consideration offered to shareholders [1]. - STAAR's largest shareholder has expressed serious concerns regarding the fairness and integrity of the sales process, indicating that the acquisition may not be in the best interest of STAAR's shareholders [1].

Core Viewpoint - Alcon has successfully completed the waiting period for its acquisition of STAAR Surgical Company under the Hart-Scott-Rodino Antitrust Improvements Act, indicating progress in the acquisition process [1] Company Summary - Alcon is recognized as a global leader in eye care, focusing on enhancing vision for individuals [1] - STAAR Surgical Company is known for manufacturing the Implantable Collamer® Lens (ICL), a significant product in the eye care industry [1] Regulatory Summary - The waiting period under the Hart-Scott-Rodino Antitrust Improvements Act expired at 11:59 p.m. ET on September 29, 2025, allowing Alcon to move forward with the acquisition of STAAR [1]

Group 1 - Halper Sadeh LLC is investigating STAAR Surgical Company for potential violations related to its sale to Alcon at $28.00 per share in cash [1] - CyberArk Software Ltd. is being investigated for its sale to Palo Alto Networks for $45.00 in cash and 2.2005 shares of Palo Alto common stock for each CyberArk share [2] - The firm may seek increased consideration for shareholders and additional disclosures regarding the proposed transactions [3] Group 2 - Shareholders are encouraged to contact Halper Sadeh LLC to discuss their legal rights and options at no charge [4] - Halper Sadeh LLC represents investors globally who have experienced securities fraud and corporate misconduct, recovering millions for defrauded investors [4]

Core Viewpoint - Kaskela Law LLC is investigating the fairness of the proposed buyout of STAAR Surgical Company by Alcon at a price of $28.00 per share, which is significantly lower than the company's recent trading prices and 52-week high [1][3]. Group 1: Buyout Details - On August 5, 2025, STAAR announced its agreement to be acquired by Alcon for $28.00 per share in cash [2]. - Many STAAR shareholders purchased their shares at prices above $30.00, indicating potential dissatisfaction with the buyout price [2]. Group 2: Investigation Focus - The investigation aims to determine if STAAR investors are receiving adequate monetary consideration for their shares [3]. - It will also assess whether the company's officers or directors breached their fiduciary duties or violated securities laws in agreeing to the buyout price [3]. Group 3: Shareholder Impact - The proposed buyout price of $28.00 per share is notably lower than STAAR's 52-week high of $38.60 per share, raising concerns among investors [3].

Core Insights - STAAR Surgical Company, a leader in phakic IOLs, announced the expiration of the 45-day "window shop" period related to its merger agreement with Alcon, with no competing acquisition proposals received [1] Company Summary - STAAR Surgical Company specializes in the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction [1] - The merger agreement with Alcon affiliates remains intact following the expiration of the "window shop" period [1] Industry Context - The expiration of the "window shop" period indicates a stable environment for STAAR Surgical's merger with Alcon, suggesting confidence in the deal's progression [1]